Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 10/20 | 0.84 |
| ▸ | SLC14A1 | Q13336 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15287958 | 0.91 | MAPT (0.84) | MAPTRXFP1TP53HTR6SLC14A1 | |
| SCHEMBL15287661 | 0.91 | HTR6 (1.00) | MAPTRXFP1TP53HTR6SLC14A1 | |
| SCHEMBL15287899 | 0.89 | MAPT (0.81) | MAPTRXFP1TP53HTR6SLC14A1 | |
| SCHEMBL15285336 | 0.89 | MAPT (1.00) | MAPTRXFP1TP53HTR6SLC14A1 | |
| SCHEMBL15287920 | 0.88 | MAPT (1.00) | MAPTRXFP1TP53HTR6SLC14A1 | |
| SCHEMBL15285224 | 0.88 | HTR6 (0.82) | MAPTRXFP1TP53HTR6SLC14A1 | |
| SCHEMBL15287694 | 0.87 | MAPT (0.79) | MAPTRXFP1TP53HTR6SLC14A1 | |
| SCHEMBL15285274 | 0.87 | MAPT (0.84) | MAPTRXFP1TP53HTR6SLC14A1 | |
| SCHEMBL15285338 | 0.86 | HTR6 (1.00) | MAPTRXFP1TP53HTR6SLC14A1 | |
| SCHEMBL8031178 | 0.86 | HTR6 (0.85) | MAPTRXFP1TP53HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303042-B2 | Triazolothienopyrimidine compound inhibitors of urea transporters and methods of using inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-05 | — | — | US | claimed |
| US-20150057274-A1 | TRIAZOLOTHIENOPYRIMIDINE COMPOUND INHIBITORS OF UREA TRANSPORTERS AND METHODS OF USING INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-26 | — | — | US | claimed |
| WO-2013148813-A1 | TRIAZOLOTHIENOPYRIMIDINE COMPOUND INHIBITORS OF UREA TRANSPORTERS AND METHODS OF USING INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-03 | — | — | WO | claimed |
| US-9303042-B2 | Triazolothienopyrimidine compound inhibitors of urea transporters and methods of using inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150057274-A1 | TRIAZOLOTHIENOPYRIMIDINE COMPOUND INHIBITORS OF UREA TRANSPORTERS AND METHODS OF USING INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-26 | — | — | US | disclosed |
| WO-2013148813-A1 | TRIAZOLOTHIENOPYRIMIDINE COMPOUND INHIBITORS OF UREA TRANSPORTERS AND METHODS OF USING INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-03 | — | — | WO | disclosed |
| WO-2009093934-A2 | SUBSTITUTED 3-SULPHONYL-[1,2,3]TRIAZOLO [1,5-A]PYRIMIDINES-ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, MEDICINAL SUBSTANCE, PHARMACEUTICAL COMPOSITION, MEDICINAL PREPARATION AND METHODS FOR THE PRODUCTION THEREOF | ALLA CHEM, LLC (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057274-A1 | TRIAZOLOTHIENOPYRIMIDINE COMPOUND INHIBITORS OF UREA TRANSPORTERS AND METHODS OF USING INHIBITORS | SLC14A1, SLC29A2, SLC29A1 | MAPT 1066/4885RXFP1 1785/4885TP53 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.